C
Cardurion Pharmaceuticals
Translating the science of cardiac myocyte signaling pathways into groundbreaking therapeutics
About Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a biotechnology startup that operates in the healthcare sector, specifically in the development of innovative cardiovascular medicines. The company's primary focus is on groundbreaking clinical programs in PDE9 and CaMKII inhibition. In simpler terms, Cardurion is working on creating drugs that can inhibit or block certain enzymes (PDE9 and CaMKII) in the body, which are believed to play a significant role in heart diseases.
Read full description
The company's clients are primarily healthcare providers and patients suffering from cardiovascular diseases. By developing novel treatments, Cardurion aims to address the unmet medical needs in the cardiovascular disease market, which is one of the leading causes of death globally.
Cardurion's business model revolves around research and development (R&D), clinical trials, and commercialization of their drugs. The company invests heavily in R&D to discover and develop potential treatments. Once a drug shows promise, it undergoes rigorous clinical trials to test its safety and effectiveness. If the drug passes these trials, it is then commercialized and sold to healthcare providers. The revenue is generated from the sales of these drugs.
In summary, Cardurion Pharmaceuticals is a promising startup in the biotech sector, focusing on the development of innovative treatments for cardiovascular diseases. It operates in a high-demand market and has a business model centered around the research, development, and commercialization of novel drugs.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Burlington, United States
- Employees
- 77
- Open positions
- 1
- Dealroom signal
- 76.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Cardurion Pharmaceuticals.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2024 | $260M | $1B | Invus · Blue Owl Capital · Farallon Capital Management · GV | ↗ |
| DEBTDebt | Jan 2023 | $18M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Cardurion Pharmaceuticals is 4.1K monthly website visits, up 41.4% over the last three months. Cardurion Pharmaceuticals's team declined 4.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Bain Capital Life Sciences- BEBain Capital Private Equity
Ascenta Capital
Invus
Blue Owl Capital
Farallon Capital Management
GV
NEA
Fidelity Investments
Delos Capital
Digitalis Ventures
Millennium Management
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cardurion Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cardurion Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.